%0 Journal Article
%A Gutierrez, Antonio
%A Bento, Leyre
%A Novelli, Silvana
%A Martin, Alejandro
%A Gutierrez, Gonzalo
%A Queralt Salas, Maria
%A Bastos-Oreiro, Mariana
%A Perez, Ariadna
%A Hernani, Rafael
%A Cruz Viguria, Maria
%A Lopez-Godino, Oriana
%A Montoro, Juan
%A Piñana, Jose Luis
%A Ferra, Christelle
%A Parody, Rocio
%A Martin, Carmen
%A Español, Ignacio
%A Yañez, Lucrecia
%A Rodriguez, Guillermo
%A Zanabili, Joud
%A Herrera, Pilar
%A Varela, Maria Rosario
%A Sampol, Antonia
%A Solano, Carlos
%A Caballero, Dolores
%T Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience.
%D 2022
%@ 2072-6694
%U http://hdl.handle.net/10668/20899
%X Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relapse, and GVHD. We included 135 patients, most (85%) receiving RIC. After a median follow-up of 68 months, 5-year EFS and OS were 47 and 50%, respectively. Overall and CR rates were 86 and 80%. The CI of relapse at 1 and 3 years were 7 and 12%. NRM at day 100 and 1 year were 17 and 32%. Previous ASCT and Grade 3-4 aGVHD were associated with a higher NRM. Grade 3-4 aGVHD, donor type (mismatch non-related), and the time-period 2006-2020 were independently related to worse EFS. Patients from 1995-2005 were younger, most from HLA-identical sibling donors, and were pretreated less. Our data confirmed that allo-SCT may be a curative option in R/R MCL with low a CI of relapse, although NRM is still high, being mainly secondary to aGVHD. The arrival of new, highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, far away from the optimal timing of treatment.
%K CAR-T cell therapy
%K Acute graft-versus-host disease
%K Allogeneic stem-cell transplantation
%K Graft-versus-lymphoma effect
%K Mantle cell lymphoma
%K Non-relapse mortality
%K Target therapy
%~